论文部分内容阅读
目的探讨局部热疗联合维A酸、重组人干扰素(rhIFN)三联疗法治疗扁平疣的临床疗效。方法选取2014年1月至2015年8月期间我院收治的扁平疣患者180例,按照就诊顺序分为治疗组和对照组各90例。对照组予以rhIFN-α2b、维A酸治疗,治疗组在对照组基础上给予局部热疗。记录并分析两组的HPV基因型检出情况、临床疗效、不良反应以及复发率。结果180例患者中共167例检出HPV DNA阳性,检出率为92.78%,检出基因型为HPV-6、HPV-11、HPV-18、HPV-58、HPV-59。其中109例(60.56%)为单一感染,54例(30.00%)为二重感染,4例(2.22%)为三重感染。两组的治疗总有效率比较无明显差异(P>0.05),但治疗组的愈显率显著高于对照组(95.56%vs 81.11%,P<0.05)。两组的不良反应发生率比较无明显差异(P>0.05),但治疗后3个月、6个月及12个月,治疗组的复发率均显著低于对照组(P<0.05)。结论局部热疗联合维A酸、rhIFN-α2b三联疗法治疗扁平疣能够提高临床疗效,降低复发率,值得推广应用。
Objective To investigate the clinical efficacy of local hyperthermia combined with tretinoin and rhIFN triple therapy in the treatment of flat warts. Methods 180 patients with flat warts admitted in our hospital from January 2014 to August 2015 were divided into treatment group and control group according to the order of treatment. The control group was given rhIFN-α2b, Victoria A acid treatment group in the control group on the basis of local hyperthermia. Record and analyze the HPV genotypes detection, clinical efficacy, adverse reactions and recurrence rate in both groups. Results The positive rate of HPV DNA was detected in 167 out of 180 patients (92.78%). The genotypes were HPV-6, HPV-11, HPV-18, HPV-58 and HPV-59. Among them, 109 cases (60.56%) were single infection, 54 cases (30.00%) were double infection and 4 cases (2.22%) were triple infection. The total effective rate was no significant difference between the two groups (P> 0.05), but the cure rate in the treatment group was significantly higher than that in the control group (95.56% vs 81.11%, P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). However, the relapse rates of the treatment group were significantly lower than those of the control group at 3 months, 6 months and 12 months after treatment (P <0.05). Conclusion Local hyperthermia combined with tretinoin, rhIFN-α2b triple therapy for the treatment of flat warts can improve clinical efficacy and reduce the recurrence rate, it is worth promoting the application.